CVS raised its full-year outlook modestly despite a Q2 earnings surge driven by lower health benefit costs.
CVS Health reported Q2 earnings that surpassed forecasts as health benefit costs declined as a share of premiums. The company increased its full-year outlook, but the hike was smaller than the Q2 beat.
Shares initially rose before reversing sharply lower. CVS had outperformed the managed-care sector since early 2025. Analysts noted management’s cautious approach to guidance.
The stock’s decline followed a separate decision by CVS Caremark to delay a formulary decision on ARS Pharmaceuticals’ epinephrine spray, Neffy until January 2026, which triggered a collapse in ARS stock.